New Zealand reports first death linked to Pfizer Covid-19 vaccine

The health ministry said other medical issues at the same time could have influenced the outcome after vaccination


Reuters August 30, 2021
Doses of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine are ready to be administered at Brigham and Women's Hospital in Boston, Massachusetts, U.S., December 16, 2020. REUTERS

WELLINGTON:

New Zealand reported its first recorded death linked to U.S. drugmaker Pfizer's COVID-19 vaccine, the health ministry said on Monday, after a woman suffered a rare side effect leading to inflammation of her heart muscle.

The news of the death comes as the country battles an outbreak of the Delta variant after nearly six months of being virus free. It followed a review by an independent panel monitoring the safety of the vaccines.

"This is the first case in New Zealand where a death in the days following vaccination has been linked to the Pfizer COVID-19 vaccine," the ministry said in a statement, without giving the woman's age.

The vaccine monitoring panel attributed the death to myocarditis, a rare, but known, side effect of the Pfizer vaccine, the ministry added.

Myocarditis is an inflammation of the heart muscle that can limit the organ's ability to pump blood and can cause changes in heartbeat rhythms.

In response, Pfizer said it  recognised there could be rare reports of myocarditis after vaccinations, but such side effects were extremely rare.

"Pfizer takes adverse events that are potentially associated with our vaccine very seriously," it told Reuters.

"We closely monitor all such events and collect relevant information to share with worldwide regulatory authorities."

The health ministry said other medical issues at the same time could have influenced the outcome after vaccination.

But the vaccine's benefit outstripped risks from side effects, it added.

"The benefits of vaccination with the Pfizer COVID-19 vaccine continue to greatly outweigh the risk of both COVID-19 infection and vaccine side effects, including myocarditis."

New Zealand has provisionally approved use of the Pfizer/BioNTech, Janssen and AstraZeneca vaccines, but only the Pfizer produced vaccine has been approved for rollout to the public.

Monday's 53 new cases took New Zealand's tally of infections in the current outbreak to 562, amid a nationwide lockdown enforced this month to limit spread of the Delta variant.

COMMENTS

Replying to X

Comments are moderated and generally will be posted if they are on-topic and not abusive.

For more information, please see our Comments FAQ

E-Publications

Most Read